Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Membrane |
Domain |
PF00067 Cytochrome P450 |
Function |
Catalyzes the conversion of all-trans retinol (also called vitamin A1, the precursor of 11-cis retinal) to 3,4-didehydroretinol (also called vitamin A2, the precursor of 11-cis 3,4-didehydroretinal). Also acts on all-trans retinal and all-trans retinoic acid. |
Biological Process | - |
Molecular Function |
GO:0004497 monooxygenase activity GO:0005506 iron ion binding GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0020037 heme binding GO:0046906 tetrapyrrole binding |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CYP27C1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CYP27C1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CYP27C1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of CYP27C1 in various data sets.
|
Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CYP27C1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CYP27C1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CYP27C1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CYP27C1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CYP27C1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CYP27C1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CYP27C1 |
Name | cytochrome P450, family 27, subfamily C, polypeptide 1 |
Aliases | FLJ16008; cytochrome P450, family 27, subfamily C, polypeptide 13; Cytochrome P450 27C1 |
Chromosomal Location | 2q14.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CYP27C1 collected from DrugBank database. |
There is no record. |